Broadly Neutralizing Antibodies for HIV Eradication View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-02-03

AUTHORS

Kathryn E. Stephenson, Dan H. Barouch

ABSTRACT

Passive transfer of antibodies has long been considered a potential treatment modality for infectious diseases, including HIV. Early efforts to use antibodies to suppress HIV replication, however, were largely unsuccessful, as the antibodies that were studied neutralized only a relatively narrow spectrum of viral strains and were not very potent. Recent advances have led to the discovery of a large portfolio of human monoclonal antibodies that are broadly neutralizing across many HIV-1 subtypes and are also substantially more potent. These antibodies target multiple different epitopes on the HIV envelope, thus allowing for the development of antibody combinations. In this review, we discuss the application of broadly neutralizing antibodies (bNAbs) for HIV treatment and HIV eradication strategies. We highlight bNAbs that target key epitopes, such as the CD4 binding site and the V2/V3-glycan-dependent sites, and we discuss several bNAbs that are currently in the clinical development pipeline. More... »

PAGES

31-37

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11904-016-0299-7

DOI

http://dx.doi.org/10.1007/s11904-016-0299-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1005667407

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26841901


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Neutralizing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Viral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Binding Sites", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epitopes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Envelope Protein gp120", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV-1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy, Adoptive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peptide Fragments", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Viral Envelope Proteins", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Ragon Institute of MGH, MIT, and Harvard, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.461656.6", 
          "name": [
            "Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-1043, 330 Brookline Avenue, 02215, Boston, MA, USA", 
            "Ragon Institute of MGH, MIT, and Harvard, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stephenson", 
        "givenName": "Kathryn E.", 
        "id": "sg:person.01251576771.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251576771.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ragon Institute of MGH, MIT, and Harvard, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.461656.6", 
          "name": [
            "Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-1043, 330 Brookline Avenue, 02215, Boston, MA, USA", 
            "Ragon Institute of MGH, MIT, and Harvard, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barouch", 
        "givenName": "Dan H.", 
        "id": "sg:person.0644324362.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644324362.10"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nature12746", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029594927", 
          "https://doi.org/10.1038/nature12746"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm1244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003729367", 
          "https://doi.org/10.1038/nm1244"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature10696", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016437859", 
          "https://doi.org/10.1038/nature10696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature13036", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032264965", 
          "https://doi.org/10.1038/nature13036"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature14411", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045337010", 
          "https://doi.org/10.1038/nature14411"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature12744", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025637640", 
          "https://doi.org/10.1038/nature12744"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature10373", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044845665", 
          "https://doi.org/10.1038/nature10373"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-02-03", 
    "datePublishedReg": "2016-02-03", 
    "description": "Passive transfer of antibodies has long been considered a potential treatment modality for infectious diseases, including HIV. Early efforts to use antibodies to suppress HIV replication, however, were largely unsuccessful, as the antibodies that were studied neutralized only a relatively narrow spectrum of viral strains and were not very potent. Recent advances have led to the discovery of a large portfolio of human monoclonal antibodies that are broadly neutralizing across many HIV-1 subtypes and are also substantially more potent. These antibodies target multiple different epitopes on the HIV envelope, thus allowing for the development of antibody combinations. In this review, we discuss the application of broadly neutralizing antibodies (bNAbs) for HIV treatment and HIV eradication strategies. We highlight bNAbs that target key epitopes, such as the CD4 binding site and the V2/V3-glycan-dependent sites, and we discuss several bNAbs that are currently in the clinical development pipeline.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11904-016-0299-7", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1034743", 
        "issn": [
          "1548-3568", 
          "1548-3576"
        ], 
        "name": "Current HIV/AIDS Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "HIV eradication strategies", 
      "HIV-1 subtypes", 
      "potential treatment modality", 
      "human monoclonal antibody", 
      "clinical development pipeline", 
      "HIV eradication", 
      "HIV replication", 
      "HIV treatment", 
      "neutralizing antibodies", 
      "treatment modalities", 
      "passive transfer", 
      "HIV envelope", 
      "antibody combinations", 
      "infectious diseases", 
      "viral strains", 
      "different epitopes", 
      "monoclonal antibodies", 
      "key epitopes", 
      "antibodies", 
      "eradication strategies", 
      "development pipeline", 
      "epitopes", 
      "dependent sites", 
      "CD4", 
      "HIV", 
      "bnAbs", 
      "subtypes", 
      "disease", 
      "narrow spectrum", 
      "eradication", 
      "modalities", 
      "treatment", 
      "recent advances", 
      "review", 
      "replication", 
      "sites", 
      "strains", 
      "V2", 
      "advances", 
      "combination", 
      "development", 
      "strategies", 
      "discovery", 
      "efforts", 
      "early efforts", 
      "envelope", 
      "transfer", 
      "spectra", 
      "applications", 
      "pipeline", 
      "large portfolio", 
      "portfolio"
    ], 
    "name": "Broadly Neutralizing Antibodies for HIV Eradication", 
    "pagination": "31-37", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1005667407"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11904-016-0299-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26841901"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11904-016-0299-7", 
      "https://app.dimensions.ai/details/publication/pub.1005667407"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_700.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11904-016-0299-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11904-016-0299-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11904-016-0299-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11904-016-0299-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11904-016-0299-7'


 

This table displays all metadata directly associated to this object as RDF triples.

202 TRIPLES      22 PREDICATES      98 URIs      82 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11904-016-0299-7 schema:about N1ecfbbe87aa74adbbe3b25497ed4fa79
2 N326623a46c3447dc8f7ac99753ace5d2
3 N4f0d206d71db4cec8df50eb5e224ad13
4 N7ea6b865f5754d719df87e295c524e70
5 N8d06d77c9f0c4168bf02b7bba3b710bb
6 N97cfe927f9f644b0b9320c7ea622bf26
7 Na00038ec0eb84d1f83587e0108c15a5a
8 Nb17f2d37d6b54559a07f4f524c7647cb
9 Nc4f1b5d2fa8c49e4a92544616e5fcb88
10 Nce560dc5adb9450598e860e7208f061c
11 Ne59ee120d2e242de922ea3bc374339c1
12 Nf6510c0567f54e68889d52ac1a6aa3c6
13 anzsrc-for:11
14 anzsrc-for:1103
15 anzsrc-for:1107
16 schema:author Ndc79074d39a040958f23692638e27f45
17 schema:citation sg:pub.10.1038/nature10373
18 sg:pub.10.1038/nature10696
19 sg:pub.10.1038/nature12744
20 sg:pub.10.1038/nature12746
21 sg:pub.10.1038/nature13036
22 sg:pub.10.1038/nature14411
23 sg:pub.10.1038/nm1244
24 schema:datePublished 2016-02-03
25 schema:datePublishedReg 2016-02-03
26 schema:description Passive transfer of antibodies has long been considered a potential treatment modality for infectious diseases, including HIV. Early efforts to use antibodies to suppress HIV replication, however, were largely unsuccessful, as the antibodies that were studied neutralized only a relatively narrow spectrum of viral strains and were not very potent. Recent advances have led to the discovery of a large portfolio of human monoclonal antibodies that are broadly neutralizing across many HIV-1 subtypes and are also substantially more potent. These antibodies target multiple different epitopes on the HIV envelope, thus allowing for the development of antibody combinations. In this review, we discuss the application of broadly neutralizing antibodies (bNAbs) for HIV treatment and HIV eradication strategies. We highlight bNAbs that target key epitopes, such as the CD4 binding site and the V2/V3-glycan-dependent sites, and we discuss several bNAbs that are currently in the clinical development pipeline.
27 schema:genre article
28 schema:inLanguage en
29 schema:isAccessibleForFree true
30 schema:isPartOf N2a6bbe188fc644c9b1e4e0c7af70f545
31 Neb6be4677ede4122843b5bc8c60b7145
32 sg:journal.1034743
33 schema:keywords CD4
34 HIV
35 HIV envelope
36 HIV eradication
37 HIV eradication strategies
38 HIV replication
39 HIV treatment
40 HIV-1 subtypes
41 V2
42 advances
43 antibodies
44 antibody combinations
45 applications
46 bnAbs
47 clinical development pipeline
48 combination
49 dependent sites
50 development
51 development pipeline
52 different epitopes
53 discovery
54 disease
55 early efforts
56 efforts
57 envelope
58 epitopes
59 eradication
60 eradication strategies
61 human monoclonal antibody
62 infectious diseases
63 key epitopes
64 large portfolio
65 modalities
66 monoclonal antibodies
67 narrow spectrum
68 neutralizing antibodies
69 passive transfer
70 pipeline
71 portfolio
72 potential treatment modality
73 recent advances
74 replication
75 review
76 sites
77 spectra
78 strains
79 strategies
80 subtypes
81 transfer
82 treatment
83 treatment modalities
84 viral strains
85 schema:name Broadly Neutralizing Antibodies for HIV Eradication
86 schema:pagination 31-37
87 schema:productId N44c22a8b890d4bd8a9f376180ea4ab90
88 N6b3a44b70652468c9bb4babb9e5d3f40
89 Nb286b80941a741f3be304ad46b540278
90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005667407
91 https://doi.org/10.1007/s11904-016-0299-7
92 schema:sdDatePublished 2022-05-20T07:31
93 schema:sdLicense https://scigraph.springernature.com/explorer/license/
94 schema:sdPublisher Nae8eb82d2d394ca6b68af31a386690f2
95 schema:url https://doi.org/10.1007/s11904-016-0299-7
96 sgo:license sg:explorer/license/
97 sgo:sdDataset articles
98 rdf:type schema:ScholarlyArticle
99 N1ecfbbe87aa74adbbe3b25497ed4fa79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Antibodies, Monoclonal
101 rdf:type schema:DefinedTerm
102 N2a6bbe188fc644c9b1e4e0c7af70f545 schema:issueNumber 1
103 rdf:type schema:PublicationIssue
104 N326623a46c3447dc8f7ac99753ace5d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Binding Sites
106 rdf:type schema:DefinedTerm
107 N44c22a8b890d4bd8a9f376180ea4ab90 schema:name dimensions_id
108 schema:value pub.1005667407
109 rdf:type schema:PropertyValue
110 N4f0d206d71db4cec8df50eb5e224ad13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Epitopes
112 rdf:type schema:DefinedTerm
113 N6b3a44b70652468c9bb4babb9e5d3f40 schema:name pubmed_id
114 schema:value 26841901
115 rdf:type schema:PropertyValue
116 N7ea6b865f5754d719df87e295c524e70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Antibodies, Viral
118 rdf:type schema:DefinedTerm
119 N8d06d77c9f0c4168bf02b7bba3b710bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Peptide Fragments
121 rdf:type schema:DefinedTerm
122 N97cfe927f9f644b0b9320c7ea622bf26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name HIV Infections
124 rdf:type schema:DefinedTerm
125 Na00038ec0eb84d1f83587e0108c15a5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name HIV Envelope Protein gp120
127 rdf:type schema:DefinedTerm
128 Nae8eb82d2d394ca6b68af31a386690f2 schema:name Springer Nature - SN SciGraph project
129 rdf:type schema:Organization
130 Nb17f2d37d6b54559a07f4f524c7647cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Humans
132 rdf:type schema:DefinedTerm
133 Nb286b80941a741f3be304ad46b540278 schema:name doi
134 schema:value 10.1007/s11904-016-0299-7
135 rdf:type schema:PropertyValue
136 Nc4f1b5d2fa8c49e4a92544616e5fcb88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name HIV-1
138 rdf:type schema:DefinedTerm
139 Nce560dc5adb9450598e860e7208f061c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Immunotherapy, Adoptive
141 rdf:type schema:DefinedTerm
142 Ndc79074d39a040958f23692638e27f45 rdf:first sg:person.01251576771.89
143 rdf:rest Nfa51da6ffb704e39801958d21583dd02
144 Ne59ee120d2e242de922ea3bc374339c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Antibodies, Neutralizing
146 rdf:type schema:DefinedTerm
147 Neb6be4677ede4122843b5bc8c60b7145 schema:volumeNumber 13
148 rdf:type schema:PublicationVolume
149 Nf6510c0567f54e68889d52ac1a6aa3c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Viral Envelope Proteins
151 rdf:type schema:DefinedTerm
152 Nfa51da6ffb704e39801958d21583dd02 rdf:first sg:person.0644324362.10
153 rdf:rest rdf:nil
154 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
155 schema:name Medical and Health Sciences
156 rdf:type schema:DefinedTerm
157 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
158 schema:name Clinical Sciences
159 rdf:type schema:DefinedTerm
160 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
161 schema:name Immunology
162 rdf:type schema:DefinedTerm
163 sg:journal.1034743 schema:issn 1548-3568
164 1548-3576
165 schema:name Current HIV/AIDS Reports
166 schema:publisher Springer Nature
167 rdf:type schema:Periodical
168 sg:person.01251576771.89 schema:affiliation grid-institutes:grid.461656.6
169 schema:familyName Stephenson
170 schema:givenName Kathryn E.
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251576771.89
172 rdf:type schema:Person
173 sg:person.0644324362.10 schema:affiliation grid-institutes:grid.461656.6
174 schema:familyName Barouch
175 schema:givenName Dan H.
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644324362.10
177 rdf:type schema:Person
178 sg:pub.10.1038/nature10373 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044845665
179 https://doi.org/10.1038/nature10373
180 rdf:type schema:CreativeWork
181 sg:pub.10.1038/nature10696 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016437859
182 https://doi.org/10.1038/nature10696
183 rdf:type schema:CreativeWork
184 sg:pub.10.1038/nature12744 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025637640
185 https://doi.org/10.1038/nature12744
186 rdf:type schema:CreativeWork
187 sg:pub.10.1038/nature12746 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029594927
188 https://doi.org/10.1038/nature12746
189 rdf:type schema:CreativeWork
190 sg:pub.10.1038/nature13036 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032264965
191 https://doi.org/10.1038/nature13036
192 rdf:type schema:CreativeWork
193 sg:pub.10.1038/nature14411 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045337010
194 https://doi.org/10.1038/nature14411
195 rdf:type schema:CreativeWork
196 sg:pub.10.1038/nm1244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003729367
197 https://doi.org/10.1038/nm1244
198 rdf:type schema:CreativeWork
199 grid-institutes:grid.461656.6 schema:alternateName Ragon Institute of MGH, MIT, and Harvard, Boston, MA, USA
200 schema:name Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-1043, 330 Brookline Avenue, 02215, Boston, MA, USA
201 Ragon Institute of MGH, MIT, and Harvard, Boston, MA, USA
202 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...